Sergel
Generic Name
Omeprazole
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| sergel 20 mg powder | ৳ 7.00 | N/A |
Description
Overview of the medicine
Sergel 20 mg powder contains Omeprazole, a proton pump inhibitor used to reduce stomach acid production. It is typically prepared as an oral suspension for patients who have difficulty swallowing tablets or capsules, or for specific pediatric uses. It treats conditions like GERD, peptic ulcers, and Zollinger-Ellison syndrome.
Uses & Indications
Dosage
Adults
Standard adult dose for GERD/Erosive Esophagitis is 20 mg once daily for 4-8 weeks. For duodenal ulcer, 20 mg once daily for 2-4 weeks. For Zollinger-Ellison Syndrome, initial dose 60 mg once daily, adjusted as needed.
Elderly
No specific dose adjustment is usually required, but caution is advised due to potential age-related decrease in clearance.
Renal_impairment
No dose adjustment is generally required for renal impairment.
How to Take
The powder should be mixed with a small amount of water or other suitable liquid (e.g., apple juice) and administered orally. Do not crush or chew the granules within the powder. Administer at least 30 minutes before a meal, preferably in the morning.
Mechanism of Action
Omeprazole is a proton pump inhibitor that irreversibly blocks the H+/K+-ATPase enzyme system (the proton pump) in the gastric parietal cells. This inhibition prevents the final step of acid secretion, thereby reducing gastric acidity.
Pharmacokinetics
Onset
Within 1 hour
Excretion
Mainly excreted in urine (approximately 80%) and feces (approximately 20%).
Half life
Approximately 0.5-1 hour (plasma elimination half-life), but duration of action is much longer due to irreversible binding.
Absorption
Rapidly absorbed after oral administration, bioavailability is approximately 30-40% due to first-pass metabolism.
Metabolism
Extensively metabolized in the liver, primarily by CYP2C19 and CYP3A4.
Side Effects
Contraindications
- •Hypersensitivity to omeprazole, substituted benzimidazoles, or any component of the formulation.
- •Concomitant use with nelfinavir.
Drug Interactions
Diazepam
Decreased elimination of diazepam, leading to increased plasma concentrations. Dose adjustment of diazepam may be needed.
Warfarin
Increased INR/prothrombin time; monitor closely, especially when initiating or discontinuing omeprazole.
Clopidogrel
Omeprazole may reduce the antiplatelet effect of clopidogrel by inhibiting CYP2C19, potentially increasing cardiovascular risk. Consider alternative antiplatelet therapy or a different PPI.
Methotrexate
Possible increased methotrexate levels and toxicity, especially with high-dose methotrexate. Monitor carefully.
Storage
Store below 30°C in a cool, dry place. Protect from light and moisture. Keep out of reach and sight of children.
Overdose
Symptoms of overdose are generally mild and self-limiting, including nausea, vomiting, dizziness, abdominal pain, diarrhea, and headache. Treatment is supportive and symptomatic.
Pregnancy & Lactation
Pregnancy Category C (risk cannot be ruled out). Use only if potential benefit justifies potential risk to the fetus. Small amounts are excreted in breast milk; generally considered compatible with breastfeeding, but caution is advised, and benefits versus risks should be assessed.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from the manufacturing date, consult product packaging for exact details.
Availability
Pharmacies, hospitals
Approval Status
Approved by regulatory authorities (e.g., FDA, DGDA)
Patent Status
Off-patent (generic available)
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
